We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+66.43%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$489M
AUM Growth
-$16.5M
(-3.3%)
Cap. Flow
-$79.4M
Cap. Flow
% of AUM
-16.25%
Top 10 Holdings %
Top 10 Hldgs %
36.36%
Holding
114
New
25
Increased
12
Reduced
45
Closed
25
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.5
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Spruce Biosciences
SPRB
|
+$14.1M |
| 2 |
AstraZeneca
AZN
|
+$13.9M |
| 3 |
Sanofi
SNY
|
+$10.9M |
| 4 |
Universal Health Services
UHS
|
+$10.1M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$9.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$17M |
| 2 |
McKesson
MCK
|
+$11.8M |
| 3 |
Molina Healthcare
MOH
|
+$9.7M |
| 4 |
AMN Healthcare
AMN
|
+$9.23M |
| 5 |
Cardinal Health
CAH
|
+$8.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.86% |
| 2 | Miscellaneous | 12.29% |
| 3 | Technology | 1.08% |
| 4 | Consumer Staples | 0.76% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Curis
CRIS
$1.23M
| $39M | 7.97% |
11,891
-484
| -4% | -$581K |
2020 Q2
2 quarters
|
|
2
PUT
CEL-SCI Corp
CVM
$30.6M
| $24.7M | 5.06% |
70,687
+30,830
| +77% | +$12.2M |
2019 Q3
5 quarters
|
|
3
SPDR Gold Trust
GLD
$142B
| $18.3M | 3.74% |
102,509
-25,693
| -20% | -$4.52M |
2020 Q1
3 quarters
|
|
|
4
Spruce Biosciences
SPRB
$119M
| $15.5M | 3.17% |
+8,489
| New | +$14.1M |
2020 Q4
0 quarters
|
|
5
Coherus Oncology
CHRS
$165M
| $15M | 3.07% |
864,056
-180,105
| -17% | -$3.21M |
2019 Q2
6 quarters
|
|
|
ALBO
6
DELISTED
Albireo Pharma Inc
ALBO
| $13.3M | 2.72% |
354,210
-124,414
| -26% | -$4.52M |
2020 Q3
1 quarter
|
|
7
HCA Healthcare
HCA
$101B
| $13.3M | 2.72% |
80,745
-25,187
| -24% | -$3.68M |
2018 Q1
11 quarters
|
|
|
8
AstraZeneca
AZN
$259B
| $13.1M | 2.69% |
+131,500
| New | +$13.9M |
2020 Q4
0 quarters
|
|
9
Cigna
CI
$79B
| $13M | 2.65% |
62,265
-19,150
| -24% | -$3.76M |
2020 Q3
1 quarter
|
|
10
Cencora
COR
$65.2B
| $12.5M | 2.56% |
127,781
-36,090
| -22% | -$3.61M |
2019 Q3
5 quarters
|
|
11
DELISTED
Walgreens Boots Alliance
WBA
| $12.3M | 2.52% |
308,686
+8,592
| +3% | +$333K |
2020 Q2
2 quarters
|
|
|
HRC
12
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $12.1M | 2.47% |
123,198
-76,702
| -38% | -$7.17M |
2020 Q2
2 quarters
|
|
|
13
Universal Health Services
UHS
$11B
| $11.1M | 2.28% |
+80,843
| New | +$10.1M |
2020 Q4
0 quarters
|
|
|
14
Sanofi
SNY
$96.5B
| $10.7M | 2.19% |
+220,201
| New | +$10.9M |
2020 Q4
0 quarters
|
|
15
Amgen
AMGN
$235B
| $9.2M | 1.88% |
+40,000
| New | +$9.22M |
2020 Q4
0 quarters
|
|
|
16
AMN Healthcare
AMN
$1.55B
| $8.91M | 1.82% |
130,598
-141,635
| -52% | -$9.23M |
2020 Q3
1 quarter
|
|
17
BioMarin Pharmaceuticals
BMRN
$10.8B
| $8.84M | 1.81% |
100,844
-93,900
| -48% | -$7.44M |
2020 Q3
1 quarter
|
|
|
18
Mirum Pharmaceuticals
MIRM
$5.35B
| $8.64M | 1.77% |
+494,743
| New | +$9.73M |
2020 Q4
0 quarters
|
|
|
19
Cardinal Health
CAH
$58.7B
| $8.31M | 1.7% |
155,217
-167,263
| -52% | -$8.68M |
2020 Q2
2 quarters
|
|
|
20
McKesson
MCK
$116B
| $8.26M | 1.69% |
47,462
-70,987
| -60% | -$11.8M |
2019 Q3
5 quarters
|
|
|
HZNP
21
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $7.24M | 1.48% |
98,901
-48,599
| -33% | -$3.61M |
2020 Q3
1 quarter
|
|
22
Becton Dickinson
BDX
$52.8B
| $6.83M | 1.4% |
27,997
+11,010
| +65% | +$2.57M |
2020 Q3
1 quarter
|
|
23
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
| $6.66M | 1.36% |
690,386
-261,305
| -27% | -$2.5M |
2020 Q1
3 quarters
|
|
|
SOLY
24
DELISTED
Soliton, Inc.
SOLY
| $6.62M | 1.36% |
862,405
-162,595
| -16% | -$1.34M |
2020 Q2
2 quarters
|
|
25
Vertex Pharmaceuticals
VRTX
$129B
| $6.19M | 1.27% |
+26,200
| New | +$6.01M |
2020 Q4
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Sio Capital Management held 114 positions worth $489M, down 3.3% from $505M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sio Capital Management withdrew a net $79.4M in Q4 2020, closing 25 positions and reducing 45 holdings. Its most notable exit was Johnson & Johnson, an estimated $17M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Sio Capital Management opened a new position in Spruce Biosciences worth $15.5M.
- Sio Capital Management's largest Q4 2020 buy was Spruce Biosciences: 8,489 shares worth $15.5M.
- Sio Capital Management added most to Kura Oncology in Q4 2020, an estimated $3.55M increase.
- Sio Capital Management's biggest Q4 2020 reduction was McKesson, cutting an estimated $11.8M.
- Sio Capital Management fully exited Johnson & Johnson in Q4 2020, selling an estimated $17M.
- Sio Capital Management's ten largest holdings make up 36% of its $489M portfolio in Q4 2020.
- Sio Capital Management opened 25 new positions and closed 25 in Q4 2020.
- Sio Capital Management's portfolio value fell 3.3% quarter-over-quarter to $489M.
Based on Sio Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.